Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 December 1981Website:
http://vaxart.comNext earnings report:
02 August 2024Last dividends:
09 November 2012Next dividends:
N/APrice
after hours | Tue, 02 Jul 2024 23:56:17 GMTDividend
Analysts recommendations
Institutional Ownership
VXRT Latest News
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs — SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today provided business and cash runway updates as the Company continues to advance its oral pill vaccine platform.
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share. Gross proceeds to Vaxart from the offering are expected to be $40 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Vaxart. The offering is expected to close on or about June 17, 2024, subject to customary closing conditions.
— 10,000-subject Phase 2b study will evaluate Vaxart's next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator —
Vaxart, Inc. (NASDAQ:VXRT) held its Q1 2024 Earnings Conference Call on May 13, 2024 at 4:30 PM ET. The call included company representatives Ed Berg, Steven Lo, Sean Tucker, James Cummings, and Phil Lee. Conference call participants included Madison Britt Wynne El-Saadi from B. Riley Securities, Aseah Khan from Cantor Fitzgerald, and Liang Cheng from Jefferies. The call began with a welcome to the Vaxart Business Update and First Quarter 2024 Financial Results Conference Call.
Does VAXART, INC. (VXRT) have what it takes to be a top stock pick for momentum investors?
VAXART, INC. (VXRT) reached a significant support level, and could be a good pick for investors from a technical perspective.
Vaxart, Inc. (NASDAQ:VXRT ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Phil Lee - CFO Brant Biehn - SVP and Business Operations Edward Berg - Senior Vice President and General Counsel Conference Call Participants Mayank Mamtani - B. Riley Securities Liang Cheng - Jefferies Operator Greetings, and welcome to the Vaxart Business Update and Third Quarter 2023 Financial Results Conference Call.
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on Wednesday, October 18 and Thursday, October 19, 2023.
After losing some value lately, a hammer chart pattern has been formed for VAXART, INC. (VXRT), indicating that the stock has found support.
Start Time: 16:30 January 1, 0000 5:01 PM ET Vaxart, Inc. (NASDAQ:VXRT ) Q2 2023 Earnings Conference Call August 03, 2023, 16:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Sean Tucker - SVP and Chief Scientific Officer Phil Lee - CFO Brant Biehn - SVP and Business Operations Conference Call Participants Charles Duncan - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Operator Greetings, and welcome to the Vaxart Business Update and Second Quarter 2023 Financial Results Conference Call.
What type of business is Vaxart?
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
What sector is Vaxart in?
Vaxart is in the Healthcare sector
What industry is Vaxart in?
Vaxart is in the Biotechnology industry
What country is Vaxart from?
Vaxart is headquartered in United States
When did Vaxart go public?
Vaxart initial public offering (IPO) was on 11 December 1981
What is Vaxart website?
https://vaxart.com
Is Vaxart in the S&P 500?
No, Vaxart is not included in the S&P 500 index
Is Vaxart in the NASDAQ 100?
No, Vaxart is not included in the NASDAQ 100 index
Is Vaxart in the Dow Jones?
No, Vaxart is not included in the Dow Jones index
When does Vaxart report earnings?
The next expected earnings date for Vaxart is 02 August 2024